Please login to the form below
Indoco and Watson Pharma in deal
Indian company Indoco Remedies has signed a deal with US-based Watson Pharmaceuticals to develop generic products for the US market
Indoco Remedies has signed a deal with US-based Watson Pharmaceuticals to develop generic products for the US market.
Shares of the Mumbai-based Indoco surged 4.95 per cent on the Bombay Stock Exchange after the announcement.
Under this deal, Indoco will develop, manufacture and supply a number of products that currently have yearly sales of $679m.
Indoco's chairman and managing director Suresh G Kare has said it is a remarkable achievement to be out-licensing technology to a company of Watson's scale.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
-
Senior Leader
-
Exceptionally competitive salary
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Moderna CEO says COVID-19 vaccine will be ready for FDA submission in late November
- FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions
- PMEA Awards 2020: Results
- Send Us a Message
- CureVac says its COVID-19 vaccine can be stored at standard refrigerator temperature
- CureVac reveals early data for mRNA-based COVID-19 vaccine candidate
- Live Webinar: Patient-Centered Digital Transformation
- PMEA Awards 2020
- EU buys 160 million doses of Moderna’s COVID-19 vaccine
- Pfizer doses first patient in investigational haemophilia drug trial
- Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA
- Aurora celebrates 15 years of improving lives
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- Harness the power of data to map new patient pathways
- Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
- What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
- ...
- Rethinking our approach to infectious disease preparedness
- The importance of long-term strategic investment to prepare for the next threat that emerges...
Quick links
Infographics
